James D Chambers

Summary

Affiliation: Tufts Medical Center
Country: USA

Publications

  1. doi request reprint Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Boston Scientific, Marlborough, MA, USA Electronic address
    Health Policy 119:156-63. 2015
  2. doi request reprint Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs
    James D Chambers
    James D Chambers is an investigator at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and an assistant professor of medicine in the School of Medicine, Tufts University, in Boston, Massachusetts
    Health Aff (Millwood) 33:1751-60. 2014
  3. doi request reprint Medicare is scrutinizing evidence more tightly for national coverage determinations
    James D Chambers
    James D Chambers is an assistant professor at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, in Boston, Massachusetts
    Health Aff (Millwood) 34:253-60. 2015
  4. ncbi request reprint Potential role of network meta-analysis in value-based insurance design
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, Boston, MA 02111 E mail
    Am J Manag Care 20:641-8. 2014
  5. doi request reprint Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Pharmacoeconomics 32:729-33. 2014
  6. doi request reprint Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, School of Medicine, Tufts University, Boston, Massachusetts, USA
    Health Aff (Millwood) 32:1109-15. 2013
  7. doi request reprint Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Value Health 16:629-38. 2013
  8. doi request reprint What can we learn from the U.S. expanded end-stage renal disease bundle?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Health Policy 110:164-71. 2013
  9. doi request reprint Factors predicting Medicare national coverage: an empirical analysis
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Care 50:249-56. 2012
  10. doi request reprint Does Medicare have an implicit cost-effectiveness threshold?
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Decis Making 30:E14-27. 2010

Detail Information

Publications14

  1. doi request reprint Medicare's use of cost-effectiveness analysis for prevention (but not for treatment)
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA Boston Scientific, Marlborough, MA, USA Electronic address
    Health Policy 119:156-63. 2015
    ..What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services...
  2. doi request reprint Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs
    James D Chambers
    James D Chambers is an investigator at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, and an assistant professor of medicine in the School of Medicine, Tufts University, in Boston, Massachusetts
    Health Aff (Millwood) 33:1751-60. 2014
    ..Our study suggests that although specialty drugs often have higher costs than traditional drugs, they also tend to confer greater benefits and hence may still offer reasonable value for money...
  3. doi request reprint Medicare is scrutinizing evidence more tightly for national coverage determinations
    James D Chambers
    James D Chambers is an assistant professor at the Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, in Boston, Massachusetts
    Health Aff (Millwood) 34:253-60. 2015
    ....
  4. ncbi request reprint Potential role of network meta-analysis in value-based insurance design
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington St, Boston, MA 02111 E mail
    Am J Manag Care 20:641-8. 2014
    ..We estimated the impact of a V-BID for osteoporosis treatments using comparative effectiveness evidence and real-world data from a California health insurance plan to estimate the benefits of the design's implementation...
  5. doi request reprint Do changes in drug coverage policy point to an increased role for cost-effectiveness analysis in the USA?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Pharmacoeconomics 32:729-33. 2014
    ....
  6. doi request reprint Medicare covers the majority of FDA-approved devices and Part B drugs, but restrictions and discrepancies remain
    James D Chambers
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, School of Medicine, Tufts University, Boston, Massachusetts, USA
    Health Aff (Millwood) 32:1109-15. 2013
    ..Our findings also provide important insights for the FDA's and Medicare's pilot parallel review program...
  7. doi request reprint Illustrating potential efficiency gains from using cost-effectiveness evidence to reallocate Medicare expenditures
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Value Health 16:629-38. 2013
    ..The objective of this study was to illustrate potential efficiency gains from reallocating Medicare expenditures by using cost-effectiveness information, and the consequences for health gains among Medicare beneficiaries...
  8. doi request reprint What can we learn from the U.S. expanded end-stage renal disease bundle?
    James D Chambers
    The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Health Policy 110:164-71. 2013
    ..Bundled payment policies offer opportunities and challenges. Their success will be determined not only by impacts on cost containment, but also to the extent they encourage high quality care...
  9. doi request reprint Factors predicting Medicare national coverage: an empirical analysis
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Care 50:249-56. 2012
    ..Medicare coverage for such interventions is limited to those deemed "reasonable and necessary" for the diagnosis or treatment of an illness or injury. What constitutes reasonable and necessary has not, however, been clearly defined...
  10. doi request reprint Does Medicare have an implicit cost-effectiveness threshold?
    James D Chambers
    Health Economics Research Group, Brunel University, Uxbridge, UK
    Med Decis Making 30:E14-27. 2010
    ..Despite the huge cost of the program, the Centers for Medicare and Medicaid Services (CMS) has maintained a policy that cost-effectiveness is not considered in national coverage determinations (NCDs)...
  11. doi request reprint Medicare's enduring struggle to define "reasonable and necessary" care
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, USA
    N Engl J Med 367:1775-7. 2012
    ..In today's fiscal environment, "reasonable and necessary" warrants a closer look...
  12. doi request reprint Medicare's national coverage determinations in diagnostic radiology: examining evidence and setting limits
    Hansel Javier Otero
    Department of Radiology, Institute for Clinical Research and Health Policy Studies, Boston, MA 02111, USA
    Acad Radiol 19:1060-5. 2012
    ..To systematically review and summarize the Center for Medicare and Medicaid Services (CMS) national coverage determination (NCDs) pertaining diagnostic imaging technologies from 1999 through 2010...
  13. doi request reprint Therapies for advanced cancers pose a special challenge for health technology assessment organizations in many countries
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 31:700-8. 2012
    ..Worldwide, we demonstrate that health technology assessment organizations are struggling with cancer's "exceptionalism."..
  14. doi request reprint Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement
    Peter J Neumann
    Center for Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
    Health Aff (Millwood) 30:2329-37. 2011
    ..For the foreseeable future, they are likely to remain the exception as drug companies pursue payment models unconnected to data collection or performance assessment...